- 5 Résultats
prix le plus bas: € 11,75, prix le plus élevé: € 233,00, prix moyen: € 169,50
1
Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad Chuang Lu Editor
Commander
sur BarnesandNoble.com
€ 233,00
CommanderLien sponsorisé

Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad Chuang Lu Editor - nouveau livre

ISBN: 9780470281741

The science and applied approaches of enzyme inhibition in drug discovery and development Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of e… Plus…

new in stock. Frais d'envoizzgl. Versandkosten., Livraison non-comprise
2
Enzyme Inhibition in Drug Discovery and Development - Chuang Lu
Commander
sur BookDepository.com
€ 194,60
Envoi: € 0,001
CommanderLien sponsorisé

Chuang Lu:

Enzyme Inhibition in Drug Discovery and Development - edition reliée, livre de poche

ISBN: 9780470281741

Hardback, [PU: John Wiley & Sons Inc], This book covers the science and approaches of enzyme inhibition applied in drug discovery and drug development, including both pharmacology and pha… Plus…

Frais d'envoiVersandkostenfrei. (EUR 0.00)
3
Enzyme Inhibition in Drug Discovery and Development - Chuang Lu
Commander
sur BookDepository.com
€ 195,00
Envoi: € 0,001
CommanderLien sponsorisé
Chuang Lu:
Enzyme Inhibition in Drug Discovery and Development - edition reliée, livre de poche

ISBN: 9780470281741

Hardback, [PU: John Wiley & Sons Inc], This book covers the science and approaches of enzyme inhibition applied in drug discovery and drug development, including both pharmacology and pha… Plus…

Frais d'envoiVersandkostenfrei. (EUR 0.00)
4
Commander
sur Biblio.co.uk
$ 14,01
(environ € 11,75)
Envoi: € 10,901
CommanderLien sponsorisé
Editor-Chuang Lu; Editor-Albert P. Li:
Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad - edition reliée, livre de poche

2010, ISBN: 9780470281741

Wiley, 2010-01-07. Hardcover. Good., Wiley, 2010-01-07, 2.5

Frais d'envoi EUR 10.90 Ergodebooks
5
Commander
sur lehmanns.de
€ 213,14
Envoi: € 0,001
CommanderLien sponsorisé
Chuang Lu; Albert P. Li:
Enzyme Inhibition in Drug Discovery and Development - edition reliée, livre de poche

2009, ISBN: 9780470281741

The Good and the Bad, Hardcover, Buch, [PU: John Wiley & Sons Inc]

Frais d'envoiVersand in 10-15 Tagen, , Versandkostenfrei innerhalb der BRD. (EUR 0.00)

1Comme certaines plateformes ne transmettent pas les conditions d'expédition et que celles-ci peuvent dépendre du pays de livraison, du prix d'achat, du poids et de la taille de l'article, d'une éventuelle adhésion de la plateforme, d'une livraison directe par la plateforme ou via un prestataire tiers (Marketplace), etc. il est possible que les frais de livraison indiqués par eurolivre ne correspondent pas à ceux de la plateforme qui propose l'article.

Données bibliographiques du meilleur livre correspondant

Détails sur le livre
Enzyme Inhibition in Drug Discovery and Development

The science and applied approaches of enzyme inhibition in drug discovery and development Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development. With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the "good" inhibitions--desirable pharmacological effects--and "bad" inhibitions--drug-drug interactions and toxicity. The book discusses: * The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment * The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug-drug interactions * The inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway Through this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.

Informations détaillées sur le livre - Enzyme Inhibition in Drug Discovery and Development


EAN (ISBN-13): 9780470281741
ISBN (ISBN-10): 047028174X
Version reliée
Date de parution: 2010
Editeur: John Wiley & Sons Inc
854 Pages
Poids: 1,270 kg
Langue: eng/Englisch

Livre dans la base de données depuis 2010-08-19T12:13:25+02:00 (Zurich)
Page de détail modifiée en dernier sur 2022-02-01T11:38:54+01:00 (Zurich)
ISBN/EAN: 9780470281741

ISBN - Autres types d'écriture:
0-470-28174-X, 978-0-470-28174-1
Autres types d'écriture et termes associés:
Auteur du livre: chuang, chuan
Titre du livre: enzyme, development inhibition, the enzymes


Données de l'éditeur

Auteur: Chuang Lu; Albert P. Li
Titre: Enzyme Inhibition in Drug Discovery and Development - The Good and the Bad
Editeur: John Wiley & Sons
868 Pages
Date de parution: 2010-01-26
Poids: 1,274 kg
Langue: Anglais
195,00 € (DE)
Not available (reason unspecified)
165mm x 240mm x 43mm

BB; GB; Hardcover, Softcover / Chemie; Chemie; Pharmakologie u. Pharmazeutische Medizin; Drug Discovery & Development; Enzymes & Receptors; Medical Science; Enzyme u. Rezeptoren; Wirkstoffforschung u. -entwicklung; Enzyme; Chemistry; Medizin; Wirkstoffforschung; Pharmacology & Pharmaceutical Medicine; Chemie; Pharmakologie

PREFACE. CONTRIBUTORS. PART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES. 1. The Drug Discovery Process (Gerald T. Miwa). 2. Medicinal Chemistry of the Optimization of Enzyme Inhibitors (Geraldine Harriman, Amy Elder, and Indranath Ghosh). 3. Bioanalytical Technologies in Drug Discovery (Jing-Tao Wu). 4. Safety Biomarkers in Drug Development: Emerging Trends and Implications (Eric R. Fedyk). 5. The Role of Drug Metabolism in Drug Discovery (Tonika Bohnert and Liang-Shang Gan). 6. Applied Pharmacokinetics in Drug Discovery and Development (Hua Yang, Xingrong Liu, Anjaneya Chimalakonda, Zheng Lu, Cuiping Chen, Frank Lee, and Wen Chyi Shyu). PART II. INHIBITION OF THE DRUG METABOLIZING ENZYMES--THE UNDESIRABLE INHIBITION. 7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes (R. Scott Obach). 8. Cytochrome P450 Induction (Edward L. LeCluyse, Michael W. Sinz, Nicola Hewitt, Stephen S. Ferguson, and Jasminder Sahi). 9. Inhibition of Drug-Metabolizing Enzymes in Gastrointestinal Tract and Its Influence on the Drug-Drug Interaction Prediction (Aleksandra Galetin and J. Brian Houston). 10. Enzyme Inhibition in Various In Vitro Systems (Ping Zhou). 11. Cytochrome P450 Degradation and Its Clinical Relevance (Mingxiang Liao, Ping Kang, Bernard P. Murray, and Maria Almira Correia). 12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition (Michael B. Fisher). 13. Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes (Albert P. Li and Chuang Lu). 14. Grapefruit Juice and Its Constituents as New Esterase Inhibitors (Suresh K. Balani). 15. Transporter-Xenobiotic Interactions: An Important Aspect of Drug Development Studies (Gang Luo, Richard Ridgewell, and Thomas Guenthner). 16. Polymorphisms of Drug Transporters and Their Clinical Implications (Cindy Q. Xia and Johnny J. Yang). 17. Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation (Lisa L. von Moltke and David J. Greenblatt). 18. Predicting Interindividual Variability of Metabolic Drug-Drug Interactions: Identifying the Causes and Accounting for Them Using Systems Approach (Amin Rostami-Hodjegan). PART III. INHIBITION OF THE DRUG TARGET ENZYMES--THE DESIRABLE INHIBITION. 19. NF-ºB: Mechanism, Tumor Biology, and Inhibitors (Lenny Dang). 20. G-Protein-Coupled Receptors as Drug Targets (Wenyan Miao and Lijun Wu). 21. Pharmacological Modulation of Ion Channels for the Treatment of Chronic Pain (Yi Liu and Ning Qin). 22. Targeting the mTOR Pathway for Tumor Therapeutics (Wei Chen). 23. HIV-1 Protease Inhibitors as Antiretroviral Agents (Sergei V. Gulnik, Elena Afonina, and Michael Eissenstat). INDEX.

Autres livres qui pourraient ressembler au livre recherché:

Dernier livre similaire:
9780470538944 Enzyme Inhibition in Drug Discovery and Development (Chuang Lu; Albert P. Li)


< pour archiver...